Change in Biotie Therapies' Financial Reporting Calendar 2016

(Thomson Reuters ONE) -


BIOTIE THERAPIES CORP.                STOCK EXCHANGE RELEASE             21 June
2016, at 5.00 p.m.

Change in Biotie Therapies' Financial Reporting Calendar 2016

Due to Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) ("Biotie" or "Company")
aligning its financial reporting calendar with the financial reporting calendar
of Acorda Therapeutics, Inc., the Company announces certain changes in its
financial reporting calendar for the year 2016. Biotie will now publish its
Interim Financial Report for January to June 2016 on 28 July, 2016; the
previously announced date was 11 August 2016.

Turku, 21 June 2016

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:
Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi(at)biotie.com

DISTRIBUTION:
www.biotie.com
Nasdaq Helsinki Ltd.
Main Media

About Biotie

Biotie is a biopharmaceutical company focused on products for neurodegenerative
and psychiatric disorders. Biotie's development has delivered Selincro
(nalmefene) for alcohol dependence, which received European marketing
authorization in 2013 and is currently being rolled out across Europe by partner
H. Lundbeck A/S. The current development products include tozadenant for
Parkinson's disease, which is in Phase 3 development, and two additional
compounds which are in Phase 2 development for cognitive disorders including
Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare
fibrotic disease of the liver.

For more information, please visit www.biotie.com.






This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Biotie Therapies Oyj via GlobeNewswire
[HUG#2022196]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 21.06.2016 - 16:00 Uhr
Sprache: Deutsch
News-ID 479173
Anzahl Zeichen: 2411

contact information:
Town:

Turku

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 264 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Change in Biotie Therapies' Financial Reporting Calendar 2016"
steht unter der journalistisch-redaktionellen Verantwortung von

Biotie Therapies Oyj (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Biotie Announces Start of Clinical Study With Nepicastat (SYN117) in Cocaine Dep ...

TURKU, FINLAND -- (Marketwired) -- 05/10/13 -- BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 10 May 2013 at 9.00 a.m.Biotie Therapies today announced the start of a Phase 2 clinical study evaluating nepicastat (SYN117) in cocaine dependence. The Nat ...

Biotie: Selincro Launched in the United Kingdom ...

TURKU, FINLAND -- (Marketwired) -- 05/06/13 -- Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has launched Selincro in the United Kingdom. According to the terms of the license agreement between Biotie and Lundbeck for Selincro, B ...

Biotie: Selincro Launched in First European Markets ...

TURKU, FINLAND -- (Marketwired) -- 04/22/13 -- BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 22 April 2013 at 9:00 a.m.Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has started launching Selincro™ in the first European markets, ...

Alle Meldungen von Biotie Therapies Oyj